Retrospective Cohort Study Assessing Remdesivir Effectiveness in Hospitalized COVID-19 Patients With Renal or Hepatic Comorbidities

Clicks: 21
ID: 327018
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #296 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Individuals with COVID-19 who have underlying renal or hepatic comorbidities are at a higher risk of mortality than those without these comorbidities. Real-world data on the effectiveness of early remdesivir (RDV) initiation in these populations are limited. This study evaluated the effect of early RDV initiation on 28-day all-cause in-hospital mortality among patients in the US who were hospitalized for COVID-19 and had renal or hepatic comorbidities. METHODS: This retrospective comparative effectiveness study used patient-level medical claims and hospital chargemaster data in the US (2021-2025). Adults who received early RDV were compared with those who did not. Patients were stratified by supplemental oxygen use in the first 2 days of hospitalization. The primary endpoint was risk of 28-day all-cause in-hospital mortality, estimated using Cox proportional hazards models. RESULTS: After 1:1 propensity score matching, 22,378 patients were included in the renal cohort (11,189 per group) and 5026 patients were included in the hepatic cohort (2513 per group). There was a reduced risk of 28-day all-cause in-hospital mortality with early RDV in both the renal cohort (HR: 0.75 [95% CI: 0.68, 0.83]; P <0.01) and the hepatic cohort (HR: 0.76 [95% CI: 0.60, 0.95]; P = 0.02). The risk of mortality was significantly lower with early RDV initiation among patients who received supplemental oxygen in both cohorts and among patients in the hepatic cohort who did not receive supplemental oxygen. CONCLUSION: Early RDV initiation was associated with improved survival among patients with renal or hepatic disease who were hospitalized for COVID-19.
Reference Key
openalex_W7204903006 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Patrick O. Godwin, Valentina Shvachko, Thomas Oppelt, Chen-Yu Wang, Amos Lichtman, Mark Berry, Neera Ahuja
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag534
URL
https://doi.org/10.1093/cid/ciag534
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.